clobetasol propionate Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
prednisone and prednisolone derivatives 4452 25122-46-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clobetasol 17-propionate
  • clofenazon
  • clobetasol propionate
A derivative of PREDNISOLONE with high glucocorticoid activity and low mineralocorticoid activity. Absorbed through the skin faster than FLUOCINONIDE, it is used topically in treatment of PSORIASIS but may cause marked adrenocortical suppression.
  • Molecular weight: 466.97
  • Formula: C25H32ClFO5
  • CLOGP: 3.49
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 80.67
  • ALOGS: -5.05
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.11 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Dec. 27, 1985 FDA FOUGERA PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 247.00 14.72 156 7511 78448 46599947
Skin atrophy 155.37 14.72 48 7619 4252 46674143
Squamous cell carcinoma of skin 155.01 14.72 50 7617 5097 46673298
Neoplasm skin 53.61 14.72 15 7652 938 46677457
Cushing's syndrome 51.84 14.72 14 7653 767 46677628
Delayed myelination 46.29 14.72 6 7661 0 46678395
Product use in unapproved indication 37.45 14.72 59 7608 90214 46588181
Cushingoid 34.56 14.72 18 7649 6248 46672147
Ochronosis 33.34 14.72 6 7661 46 46678349
Psoriatic arthropathy 27.72 14.72 32 7635 36347 46642048
Resting tremor 26.29 14.72 8 7659 672 46677723
Eczema 24.68 14.72 23 7644 20377 46658018
Bronchiolitis obliterans syndrome 23.97 14.72 5 7662 88 46678307
Skin exfoliation 23.48 14.72 28 7639 32910 46645485
Alopecia scarring 23.05 14.72 5 7662 107 46678288
Skin striae 22.56 14.72 8 7659 1085 46677310
Necrotising fasciitis 21.89 14.72 10 7657 2613 46675782
Skin haemorrhage 21.75 14.72 13 7654 5878 46672517
Dermatitis bullous 21.03 14.72 14 7653 7629 46670766
Pustular psoriasis 20.62 14.72 11 7656 4006 46674389
Poikiloderma 20.46 14.72 4 7663 50 46678345
Cortisol decreased 19.14 14.72 7 7660 1037 46677358
Skin burning sensation 18.94 14.72 15 7652 10677 46667718
Product container issue 18.69 14.72 8 7659 1791 46676604
Headache 18.54 14.72 138 7529 478214 46200181
Rheumatoid arthritis 17.21 14.72 9 7658 240206 46438189
Nasal polypectomy 16.91 14.72 3 7664 21 46678374
Erythema 16.26 14.72 56 7611 142764 46535631
Cutaneous lupus erythematosus 16.08 14.72 8 7659 2521 46675874
Incorrect product administration duration 16.04 14.72 13 7654 9564 46668831
Infected dermal cyst 16.00 14.72 5 7662 459 46677936
Pterygium 15.75 14.72 4 7663 172 46678223

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 179.51 17.00 95 3898 42411 29906074
Human herpesvirus 8 infection 56.49 17.00 14 3979 675 29947810
Rash 38.33 17.00 81 3912 191808 29756677
Folliculitis 27.00 17.00 12 3981 3628 29944857
Cushing's syndrome 26.20 17.00 7 3986 455 29948030
Diarrhoea 24.19 17.00 98 3895 334005 29614480
Skin exfoliation 22.38 17.00 21 3972 23151 29925334
Cellulitis 21.87 17.00 29 3964 46755 29901730
Necrotising fasciitis 21.27 17.00 10 3983 3439 29945046
Skin atrophy 20.99 17.00 8 3985 1640 29946845
Psoriatic arthropathy 20.67 17.00 17 3976 15744 29932741
Adrenal suppression 19.67 17.00 6 3987 627 29947858
Cutaneous T-cell lymphoma 18.89 17.00 7 3986 1328 29947157
Drug ineffective 18.68 17.00 92 3901 340295 29608190
Chorioretinopathy 18.32 17.00 7 3986 1445 29947040
Human herpes virus 8 test positive 17.53 17.00 3 3990 21 29948464

Pharmacologic Action:

SourceCodeDescription
ATC D07AD01 DERMATOLOGICALS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
CORTICOSTEROIDS, PLAIN
Corticosteroids, very potent (group IV)
ATC D07CD01 DERMATOLOGICALS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS
Corticosteroids, very potent, combinations with antibiotics
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D005938 Glucocorticoids
MeSH PA D006728 Hormones
FDA EPC N0000175576 Corticosteroid
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists
CHEBI has role CHEBI:35472 anti-inflammatory drugs
CHEBI has role CHEBI:131809 smo receptor agonists

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Atopic dermatitis indication 24079001 DOID:3310
Contact dermatitis indication 40275004 DOID:2773
Seborrheic dermatitis indication 50563003 DOID:8741
Nummular eczema indication 81418003
Plaque psoriasis indication 200965009
Scalp psoriasis indication 238608008
Dermatosis of scalp indication 402694007 DOID:3136
Inflammatory dermatosis indication 703938007
Folliculitis contraindication 13600006 DOID:4409
Glaucoma contraindication 23986001 DOID:1686
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Open wound contraindication 125643001
Skin striae contraindication 201066002
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Atrophoderma contraindication 399979006
Peripheral vascular disease contraindication 400047006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.48 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST Ki 9.18 DRUG MATRIX CHEMBL
Annexin A1 Cytosolic other WOMBAT-PK
Bile salt export pump Transporter IC50 5.07 CHEMBL
Androgen receptor Transcription factor Ki 5.60 DRUG MATRIX
Progesterone receptor Transcription factor Ki 8.82 DRUG MATRIX
Bile salt export pump Unclassified IC50 4.46 CHEMBL
Glucocorticoid receptor Transcription factor IC50 8.50 CHEMBL

External reference:

IDSource
D01272 KEGG_DRUG
4018898 VUID
N0000179087 NUI
25122-41-2 SECONDARY_CAS_RN
4018898 VANDF
4019684 VANDF
C0055895 UMLSCUI
C0008992 UMLSCUI
CHEBI:31414 CHEBI
CHEBI:205919 CHEBI
CHEMBL1159650 ChEMBL_ID
DB01013 DRUGBANK_ID
D002990 MESH_DESCRIPTOR_UI
32798 PUBCHEM_CID
7062 IUPHAR_LIGAND_ID
3154 INN_ID
779619577M UNII
ADN79D536H UNII
5311051 PUBCHEM_CID
DB11750 DRUGBANK_ID
21245 RXNORM
300 MMSL
4471 MMSL
72591 MMSL
002203 NDDF
004480 NDDF
32197004 SNOMEDCT_US
419129004 SNOMEDCT_US
48614001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Clobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0162 OINTMENT 0.50 mg TOPICAL ANDA 20 sections
Clobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0163 CREAM 0.50 mg TOPICAL ANDA 20 sections
Clobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0269 SOLUTION 0.50 mg TOPICAL ANDA 18 sections
Clobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0293 GEL 0.50 mg TOPICAL ANDA 20 sections
Clobetasol Propionate (emollient) HUMAN PRESCRIPTION DRUG LABEL 1 0168-0301 CREAM 0.50 mg TOPICAL ANDA 25 sections
Clobex HUMAN PRESCRIPTION DRUG LABEL 1 0299-3847 SHAMPOO 0.05 g TOPICAL NDA 25 sections
Clobex HUMAN PRESCRIPTION DRUG LABEL 1 0299-3848 LOTION 0.05 g TOPICAL NDA 25 sections
CLOBEX HUMAN PRESCRIPTION DRUG LABEL 1 0299-3849 SPRAY 0.05 g TOPICAL NDA 25 sections
Clobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 0378-8055 AEROSOL, FOAM 0.50 mg TOPICAL NDA authorized generic 27 sections
OLUX-E HUMAN PRESCRIPTION DRUG LABEL 1 0378-8147 AEROSOL, FOAM 0.50 mg TOPICAL NDA 26 sections
clobetasol propionate HUMAN PRESCRIPTION DRUG LABEL 1 0378-8167 AEROSOL, FOAM 0.50 mg TOPICAL NDA authorized generic 26 sections
OLUX HUMAN PRESCRIPTION DRUG LABEL 1 0378-8182 AEROSOL, FOAM 0.50 mg TOPICAL NDA 26 sections
Temovate Scalp Application HUMAN PRESCRIPTION DRUG LABEL 1 0462-0269 SOLUTION 0.50 mg TOPICAL NDA 20 sections
Temovate HUMAN PRESCRIPTION DRUG LABEL 1 0462-0293 GEL 0.50 mg TOPICAL NDA 21 sections
Clobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 0472-0400 CREAM 0.50 mg TOPICAL ANDA 18 sections
Clobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 0472-0400 CREAM 0.50 mg TOPICAL ANDA 18 sections
Clobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 0472-0402 SOLUTION 0.50 mg TOPICAL ANDA 13 sections
Clobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 0472-0403 SHAMPOO 0.05 g TOPICAL ANDA 18 sections
Clobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 0472-0404 LOTION 0.05 g TOPICAL ANDA 17 sections
Clobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 0574-2063 SPRAY 0.50 mg TOPICAL ANDA 28 sections
CLOBETASOL PROPIONULLTE HUMAN PRESCRIPTION DRUG LABEL 1 0591-4039 SPRAY 0.05 g TOPICAL NDA authorized generic 25 sections
Clobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 0713-0656 OINTMENT 0.50 mg TOPICAL ANDA 19 sections
clobetasol propionate HUMAN PRESCRIPTION DRUG LABEL 1 0781-7137 SHAMPOO 0.05 g TOPICAL NDA authorized generic 25 sections
Temovate HUMAN PRESCRIPTION DRUG LABEL 1 10337-162 OINTMENT 0.50 mg TOPICAL ANDA 21 sections
Temovate HUMAN PRESCRIPTION DRUG LABEL 1 10337-163 CREAM 0.50 mg TOPICAL ANDA 21 sections
TEMOVATE E HUMAN PRESCRIPTION DRUG LABEL 1 10337-301 CREAM 0.50 mg TOPICAL ANDA 25 sections
Clobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 13668-569 CREAM 0.50 mg TOPICAL ANDA 10 sections
Clobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 13668-603 OINTMENT 0.50 mg TOPICAL ANDA 10 sections
Clobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 16714-730 CREAM 0.50 mg TOPICAL ANDA 20 sections
Clobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 16714-782 OINTMENT 0.50 mg TOPICAL ANDA 20 sections